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Canine Kidney Transplantation With FK-506 Alone or 
in Combination With Cyclosporine and Steroids 
S. Todo, A.J. Demetris, Y. Ueda, O. Imventarza, K. Okuda, A. Casavilla, S. Cemaj, A. Ghalab, 
V. Mazzaferro, B.S. Rhoe, Y. Tonghua, L. Makowka, and T.E. Starzl 
I N THIS STUDY, the new drug FK-S06 (FK) was tested in dogs for its ability to 
prevent rejection of kidneys when given alone, 
with small doses of cyclosporine or steroids, or 
both. 
MATERIALS AND METHODS 
Mongrel donors weighing 13 to 15 kg provided kidneys 
for beagle recipients of the same size under 25 mg/kg 
pentobarbital anesthesia intravenously. When needed, 
supplementary pentobarbital or ketamine, 2 mg/kg, or 
both, were given intravenously. The renal grafts were 
placed intraabdominally by connecting the renal artery 
and vein to the recipient iliac vessels and using uretero-
neocystotomies. The recipient native kidneys were 
removed at the same operation. One gram of cephalospo-
rin was given intravenously or intramuscularly during the 
operation and for three days afterwards. A diet was 
started the next day. 
All immunosuppressive drugs were given orally start-
ing on the morning after transplantation and continuing 
daily. To prevent vomiting caused by FK or other postop-
erative factors, 2 mg atropine sulphate was given intra-
muscularly twice a day for the first week and once a day 
for the second week. During the third week, the atropine 
dose was reduced to I mg/d. 
The FK was provided in powder form by the Fujisawa 
Pharmaceutical Co, Ltd, Osaka, Japan, and placed in 
commercial capsules. The dogs were docile well-trained 
beagles who allowed deep digital placement of the cap-
sules in the oropharynx. Prednisone (Pred) was given as a 
5 mg tablet. Cyclosporine (CyA) in the commercial oil 
carrier used clinically was given orally by syringe. 
FK Administration Alone 
FK was the sole immunosuppressive treatment. The 
animals were placed in four groups: I, untreated control, 
n - 6; II, FK (0.5mg/kg/d), n - 6; III, FK (1.0 
mg/kg/d), n ~ 6; and IV, FK (1.5 mg/kg/d), n = 6. 
FK in Combination 
The smallest dose in the foregoing studies (group II, 0.5 
mg/kg/d) or half this dose was combined with small 
doses of other agents as follows: group V, FK (0.5 
mg/kg/d), CyA (5.0 mg/kg/d), Pred (5.0 mg/d), n - 6; 
group VI, FK (0.25 mg/kg/d), eyA (2.50 mg/kg/d), 
Pred (2.5 mg/d), n = 6; and group VII, CyA (5.0 
mg/kg/d), Pred (5.0 mg/d), n - 6. 
The results in group II were considered to be a single-
agent control for those obtained with the triple-drug 
combination of group V. The animals of group VII who 
received CyA and Pred were considered controls for the 
triple-drug, FK-containing regimen of group V. 
Biochemical and Pathological Studies 
Blood samples were taken every three mornings for the 
measurement of levels of blood urea nitrogen, creatinine, 
SGOT, and total bilirubin. Complete postmortem exami-
nation was performed immediately after the animals died. 
Tissues were fixed with formalin and stained with hema-
toxylin and eosin. Histopathologic changes were scored 
blindly according to a subjective scale from I to 4. 
Statistics 
The Wilcoxon rank sum test and Student's t test were 
applied for the stitistical analysis. 
RESULTS 
The outcome in each individual experiment 
is summarized in 'Table 1. The untreated 
animals died of rejection in eight to 19 days. 
Survival was significantly prolonged with all 
doses of FK, the best results being with 1.S 
mg/kg. With this high dose, rejection as 
judged histopathologically was absent or mild 
in the two animals who provided tissue for 
histopathologic analysis. The other four are 
alive after 39 to 71 days. Increases in serum 
creatinine levels caused by rejection were 
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Table 1. Effect of FK Dose on Results of Canine Kidney Transplantation 
Latest Value Histological OralOosage Animal Cause of Severity of 
Groups (mg/kg/d) No. Survival (d) Oeath BUN (mg/d..) Cr (mg/d..) Rejection 
0 3 19 Rejection 359 14.1 Severe 
4 9 Rejection 154 8.2 Severe 
5 12 Rejection 142 16.0 Severe 
6 11 Rejection 271 13.5 Severe 
7 8 Rejection 193 13.0 Severe 
8 11 Rejection 135 8.7 Severe 
\I 0.5 102 16 Rejection 172 13.5 Moderate 
104 24 Intussusception 44 1.1 Mild 
109 >70 77 4.3 
112 44 Rejection 195 5.1 Moderate 
121 13 Rejection 336 7.7 Moderate 
122 28 Rejection 140 14.4 Severe 
III 1.0 101 37 Unknown 154 2.5 Moderate 
105 63 Unknown 24 1.0 Severe 
108 16 Rejection 219 6.3 Severe 
114 21 Unknown 59 2.9 Severe 
123 14 Unknown 39 2.0 None 
124 35 Unknown 41 1.5 Moderate 
IV 1.5 103 >71 20 1.0 
107 28 Pancreatitis (?) 108 8.8 Mild 
113 >67 20 1.3 
125 17 Unknown 42 1.2 None 
127 >44 19 0.9 
133 >39 95 4.0 
Abbreviation: Cr. creatinine. 
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Fig 1. Influence of FK dose on serum creatinine level. The rises in the serum creatinine concentration in animals 
of all groups were usually celJsed by rejection. 
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Table 2. Histological Changes in Extrarenal Organs After Kidney Transplantation Under FK 
Liver HeM! Pancreas: 
" Acinar Cell 
Dosage Swelling of Fatty Change Infarction Degeneration 
Group (mg/kg/d) Hepatocytes of Hepatocytes Arteritis (Focal Large) (Focal Necrosis) 
0 0/6 (0%) 1/6 (16%) 0/6 (0%) 0/6 (0%) 0/6 (0%) 
II 0.5 1/5 (20%) 1/5 (20%) 0/5 (0%) 0/5 (0%) 0/5 (0%) 
III 1.0 1/6 (16%) 0/6 (0%) 2/6 (33%) 2/6 (33%) 3/6 (50%) 
IV 1.5 1/2 (50%) 0/2 (0%) 1/2 (50%) 1/2 (50%) 2/2 (100%) 
minimized or avoided in animals receiving 1.0 
and 1.5 mg/kg/d (Fig O. With doses of 0.5 
mg/kg/d, rejection was always found histo-
pathologically (Table 1), and elevated creati-
nine levels were the rule (Fig 1). 
However, animals treated with the higher 
doses of FK had significant evidence on histo-
pathologic examination of toxicity involving 
the liver, heart, and pancreas (Table 2). The 
findings were similar to those reported else-
where in this symposium in dogs not subjected 
to transplantation. 
Vomiting and weight loss were common in 
all of the treatment groups. Severe emaciation 
with loss of more than 30% of the body weight 
was seen in four of the 18 FK-treated animals. 
Two animals each in groups II and III died 
with severe rejection plus lethal emaciation. 
FK in Combination 
Five of six dogs in group V that were 
treated with 0.5 mg/kg FK, 5 mg/kg CyA, 
and 5 mg Pred are alive with normal renal 
function after 51 to 71 days. The survival 
results (Table 3) were better than those in 
group II in which 0.5 mg/kg FK was used 
alone (P < .01) and better than those in group 
VII in which 5 mg/kg Cy A and Pred were 
given (P < .01). None of the animals in group 
V lost body weight. 
The superiority of the triple-drug combina-
tion of group V was also evident from the 
serum creatinine levels (Fig 2). However, the 
three drugs when given at half dosage (group 
VI) were no longer effective (Table 3 and Fig 
2). 
Table 3. Combination Therapy With Low Doses of FK. CyA. and Prad After Canine Kidney qrans~lantation 
Treatment Dose Animal Cause of Latest Value 
Groups (Oral) No. Survival (d) Death BUN (mg/c:l.) Cr (mg/c:l.) 
V FK. 0.5 mg/kg/d 106 >71 16 1.0 
eVA, 5/0 mg/kg/d 115 23 Unknown 159 3.2 
Pred, 5.0 mg/d 116 >60 24 1.3 
118 >53 16 1.2 
119 >51 29 1.0 
120 >51 24 1.2 
VI FK, 0.25 mg/kg/d 129 13 Rejection 94 6.6 
eVA. 2.5 mg/kg/d 130 19 Rejection 113 22.4 
Pred, 2.5 mg/d 132 31 Rejection 107 6.2 
134 30 Rejection 176 11.6 
135 19 Rejection 123 6.5 
136 26 Rejection 105 9.3 
VII eyA, 5.0 mg/kg/d 137 . >24 30 1.9 
Pred, 5.0 mg/d 138 12 Rejection 288 13,3 
139 12 Rejection 181 8.9 
140 12 Rejection 147 15.5 
141 >12 120 12.5 
142 >12 52 2.8 
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Fig 2. Serum creatinine levels in dogs treated with drug combinations. Note the superior results in group V. 
DISCUSSION 
The principal studies of FK-506 in dogs by 
Ochiai et ai' and those by us2 have not yet 
been published. Ochiai's Chiba University 
group had almost universal survival after 
canine renal transplantation without much 
evidence of toxicity.' Our findings were less 
dramatic or favorable. Rejection often was not 
controlled, even at doses that led to profound 
illness or sometimes fatal emaciation. In addi-
tion, there was histopathologic evidence of 
toxicity in mUltiple extrarenal organs. 
The toxicity of dogs may be a species-
specific phenomenon. Rats have tolerated 
high-dose FK therapy wellY The effect of FK 
on subhuman primates is under study at sev-
eral institutions, but no results are available at 
this time. However, even if FK proves to have 
substantial dose-related toxicity in all species 
including humans, it could still be a valuable 
agent for clinical use. The synergism of small 
doses of FK with suboptimal doses of Cy A and 
steroids was striking in our canine experi-
ments herein reported. The results were con-
sonant with those using the same drug combi-
nation in rats submitted to heterotopic heart 
transplantation.5 With in vitro studies of 
human lymphocytes, Zeevi et al6 also have 
obtained convincing evidence for a true syner-
gism as opposed to an additive effect of FK 
and CyA. 
More and more, polypharmaceutical ther-
apy has been used to allow potent immunosup-
pressive agents to be used in doses small 
enough so that side effects inherent with high 
doses of single agents can be avoided. 
SUMMARY 
The immunosuppressive agent FK permit-
ted increased kidney transplant survival in 
dogs over a wide dose range, but with weight 
loss and manifold evidence of toxicity. The 
best use of FK at low doses was in combina-
tion with CyA and Pred. 
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